Transurethral microwave thermotherapy: What role should it play versus medical management in the treatment of benign prostatic hyperplasia?

Urology

Volumn 52, Issue 6, 1998, Pages 935-947

  Djavan, Bob ^a   Larson, Thayne R ^b   Blute, Michael L ^c   Marberger, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ALPHA ADRENERGIC RECEPTOR BLOCKING; DOSIMETRY; ENZYME INHIBITION; HUMAN; HYPERTHERMIC THERAPY; MALE; MICROWAVE IRRADIATION; MORBIDITY; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; DIATHERMY; HUMANS; MALE; MICROWAVES; PAIN; PROSTATIC HYPERPLASIA; URETHRA; URINARY RETENTION;

EID: 0032400781     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00471-3     Document Type: Review

References (100)

1. Stoner E. The clinical development of a 5 alpha-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol. 37:1990;375-378.
2. Berry S.J., Coffey D.S., Walsh P.C., et al. The development of human benign prostatic hyperplasia with age. J Urol. 132:1984;474-479.
3. Garraway W.M., Collins G.N., Lee R.J. High prevalence of benign prostatic hypertrophy in the community. Lancet. 338:1991;469-471.
4. Glynn R.J., Campion E.W., Bouchard G.R., et al. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Am J Epidemiol. 121:1985;78-90.
5. Neal D.E., Ramsden P.D., Sharples L., et al. Outcome of elective prostatectomy. BMJ. 299:1989;762-767.
6. Djavan B., Madersbacher S., Klingler C., et al. Urodynamic assessment of patients with acute urinary retention is treatment failure after prostatectomy predictable? J Urol. 158:1997;1829-1833.
7. Lanes S.F., Sulsky S., Walker A.M., et al. A cost density analysis of benign prostatic hyperplasia. Clin Ther. 18:1996;993-1004.
8. Larson T.R., Bostwick D.G., Corica A. Temperature-correlated histopathologic changes following microwave thermoablation of obstructive tissue in patients with benign prostatic hyperplasia. Urology. 47:1996;463-469.
9. de Geeter P, Scherer M, Meyer W, et al: The use of urodynamics and MRI to evaluate the long term results of transurethral microwave thermoablation of the prostate with the Targis™ system. Presented at the 24th Congress of the Société Internationale d'Urologie, Montreal, Canada, September 7-11, 1997.
10. Kaouk Z., Khebir A., Savard P. A finite element model of a microwave catheter for cardiac ablation. IEEE Trans Microwave Theory Tech. 44:1996;1848-1854.
11. Labonté S., Blais A., Legault S.R., et al. Monopole antennas for microwave catheter ablation. IEEE Trans Microwave Theory Tech. 44:1996;1832-1840.
12. Larson T.R., Blute M.L., Tri J.L., et al. Contrasting heating patterns and efficiency of the Prostatron and Targis microwave antennae for thermal treatment of benign prostatic hyperplasia. Urology. 51:1998;908-915.
13. D'Angelo M.F., Hanson K.A., King B.F., et al. Prospective comparative analysis of MRI gadolinium enhanced central zone perfusion defects using the Prostatron 2 0 and the Targis thermotherapy devices . J Urol. 159:(suppl):1998;304-312.
14. Larson T.R., Collins J.M., Corica A. Detailed interstitial temperature mapping during treatment with a novel transurethral microwave thermoablation system in patients with benign prostatic hyperplasia. J Urol. 159:1998;258-264.
15. Carter S., Ogden C. Intraprostatic temperature v. clinical outcome in T.U.M.T. Is the response heat-dose dependent? J Urol. 151:1994;416A.
16. Goldfarb B., Bartkiw T., Trachtenberg J. Microwave therapy of benign prostatic hyperplasia. Urol Clin North Am. 22:1995;431-439.
17. Netto N.R., Claro J.A. Traitement de l'hypertrophie bénigne de prostate par Prostatron® étude des effets d'une augmentation de la température de traitement . Prog Urol. 5:1995;238-244.
18. de Wildt M.J.A.M., Tubaro A., Höfner K., et al. Responders and nonresponders to transurethral microwave thermotherapy a multicenter retrospective analysis . J Urol. 154:1995;1775-1778.
19. Bolmsjö M., Wagrell L., Hallin A., et al. The heat is on - but how? A comparison of TUMT devices. Br J Urol. 78:1996;564-572.
20. Gottlieb C.F., Hagmann M.J., Babij T.M., et al. Interstitial microwave hyperthermia applicators having submillimetre diameters. Int J Hyperthermia. 6:1990;707-714.
21. Marteinsson V.T., Due J. Transurethral microwave thermotherapy for uncomplicated benign prostatic hyperplasia a prospective study with emphasis on symptomatic improvement and complications . Scand J Urol Nephrol. 28:1994;83-89.
22. Barry M.J., Fowler F.J. Jr, Bin L., et al. A nationwide survey of practicing urologists current management of benign prostatic hyperplasia and clinically localized prostate cancer . J Urol. 158:1997;488-492.
23. Larson T.R., Blute M.L., Bruskewitz R.C., et al. A high efficiency microwave thermoablation system in the treatment of benign prostatic hyperplasia results of a randomized, sham-controlled, prospective, double-blind, multicenter clinical trial . Urology. 51:1998;731-742.
24. Netto N.R., de Lima M.L., de Almeida Claro J., et al. The importance of the prostate weight in transurethral microwave thermotherapy. Arch Esp Urol. 48:1995;413-417.
25. Ramsey E.W., Miller P.D., Parsons K. A novel transurethral microwave thermoablation system to treat benign prostatic hyperplasia results of a prospective multicenter clinical trial . J Urol. 158:1997;112-119.
26. Belot G., Chive M. Transurethral thermotherapy of the benign prostate hypertrophy controlled by radiometry. Eur Urol. 23:1993;326-329.
27. Bunce C.J., Bdesha A.S., Dinneen M., et al. Transurethral microwave therapy patient selection and outcome . Eur Urol. 26:1994;298-302.
28. Witjes W.P., Rosier P.F., Caris C.T., et al. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction a stratified analysis . Urology. 49:1997;197-205.
29. Boyle P., Gould A.L., Roehrborn C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride meta-analysis of randomized clinical trials . Urology. 48:1996;398-405.
30. Tewari A., Shinohara K., Narayan P. Transition zone volume and transition zone ratio predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients . Urology. 45:1995;258-265.
31. Bdesha A.S., Bunce C.J., Kelleher J.P., et al. Transurethral microwave treatment for benign prostatic hypertrophy a randomised controlled clinical trial . BMJ. 306:1993;1293-1296.
32. Ogden C.W., Reddy P., Johnson H., et al. Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction. Lancet. 341:1993;14-17.
33. Bdesha A.S., Bunce C.J., Snell M.E., et al. A sham controlled trial of transurethral microwave therapy with subsequent treatment of the control group. J Urol. 152:1994;453-458.
34. de la Rosette J.J.M.C.H., de Wildt M.J.A.M., Alivizatos G., et al. Transurethral microwave thermotherapy (TUMT) in benign prostatic hyperplasia placebo versus TUMT . Urology. 44:1994;58-63.
35. Mulvin D., Creagh T., Kelly D., et al. Transurethral microwave thermotherapy versus transurethral catheter therapy for benign prostatic hyperplasia. Eur Urol. 26:1994;6-9.
36. Blute M.L., Patterson D.E., Segura J.W., et al. Transurethral microwave thermotherapy v sham treatment double-blind randomized study . J Endourol. 10:1996;565-573.
37. de Wildt M.J.A.M., Hubregtse M., Ogden C., et al. A 12-month study of the placebo effect in transurethral microwave thermotherapy. Br J Urol. 77:1996;221-227.
38. Roehrborn C.G., Preminger G., Newhall P., et al. Microwave thermotherapy for benign prostatic hyperplasia with the Dornier Urowave results of a randomized, double-blind, multicenter, sham-controlled trial . Urology. 51:1998;19-28.
39. Ramsey E.W., Miller P.D., Parsons K. Preferential heating using transurethral thermoablation (T3) improves clinical results. Proc Int Soc Opt Eng. 2970:1997;460-469.
40. Ramsey E.W., Miller P.D., Parsons K. Transurethral microwave thermotherapy in the treatment of benign prostatic hyperplasia results obtained with the Urologix T3 device . World J Urol. 16:1998;96-101.
41. Glass J.M., Bdesha A.S., Witherow R.O. Microwave thermotherapy a long-term follow-up of 67 patients from a single centre . Br J Urol. 81:1998;377-382.
42. Keijzers G.B., Francisca E.A., D'Ancona F.C., et al. Long-term results of lower energy transurethral microwave thermotherapy. J Urol. 159:1998;1966-1973.
43. Dahlstrand C., Geirsson G., Fall M., et al. Transurethral microwave thermotherapy versus transurethral resection for benign prostatic hyperplasia preliminary results of a randomized study . Eur Urol. 23:1993;292-298.
44. Dahlstrand C., Waldén M., Geirsson G., et al. Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction a prospective randomized study with a 2-year follow-up . Br J Urol. 76:1995;614-618.
45. Ahmed M., Bell T., Lawrence W.T., et al. Transurethral microwave thermotherapy (Prostatron™ version 2.5) compared with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia a randomized, controlled, parallel study . Br J Urol. 79:1997;181-185.
46. D'Ancona F.C., Francisca E.A., Witjes W.P., et al. High energy thermotherapy versus transurethral resection in the treatment of benign prostatic hyperplasia results of a prospective randomized study with 1 year of followup . J Urol. 158:1997;120-125.
47. Jardin A., Bensadoun H., Delauche-Cavallier M.C., et al. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet. 337:1991;1457-1461.
48. Lepor H., Auerbach S., Puras-Baez A., et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol. 148:1992;1467-1474.
49. Lloyd S.N., Buckley J.F., Chilton C.P., et al. Terazosin in the treatment of benign prostatic hyperplasia a multicentre, placebo-controlled trial . Br J Urol. 70:(suppl 1):1992;17-21.
50. Brawer M.K., Adams G., Epstein H. Terazosin in the treatment of benign prostatic hyperplasia. Arch Fam Med. 2:1993;929-935.
51. Hansen B.J., Nordling J., Mensink H.J., et al. Alfuzosin in the treatment of benign prostatic hyperplasia effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial . Scand J Urol Nephrol Suppl. 157:1994;169-176.
52. Fawzy A., Braun K., Lewis G.P., et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients a multicenter study . J Urol. 154:1995;105-109.
53. Gillenwater J.Y., Conn R.L., Chrysant S.G., et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension a double-blind, placebo-controlled, dose-response multicenter study . J Urol. 154:1995;110-115.
54. 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol. 29:1996;155-167.
55. Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 335:1996;533-539.
56. Roehrborn C.G., Oesterling J.E., Auerbach S., et al. The Hytrin Community Assessment Trial study a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia . Urology. 47:1996;159-168.
57. Roehrborn C.G., Siegel R.L. Safety and efficacy of doxazosin in benign prostatic hyperplasia a pooled analysis of three double-blind, placebo-controlled studies . Urology. 48:1996;406-415.
58. Abrams P. Urodynamic effects of doxazosin in men with lower urinary tract symptoms and benign prostatic obstruction. Results from three double-blind placebo-controlled studies. Eur Urol. 32:1997;39-46.
59. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology. 51:1998;892-900.
60. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia placebo-controlled, double-blind extension of phase III trial . Urology. 51:1998;901-906.
61. Elhilali M.M., Ramsey E.W., Barkin J., et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology. 47:1996;335-342.
62. Djavan B, Roehrborn CG, Shariat S, et al: Prospective, randomized comparison of high-energy transurethral microwave thermotherapy versus α-blocker treatment in patients with benign prostatic hyperplasia. J Urol (in press).
63. Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology. 45:1995;406-413.
64. Lukacs B., McCarthy C., Grange J.C. Long-term quality of life in patients with benign prostatic hypertrophy preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin . Eur Urol. 24:(suppl 1):1993;34-40.
65. Jardin A., Bensadoun H., Delauche-Cavallier M.C., et al. Long-term treatment of benign prostatic hyperplasia with alfuzosin a 24-30 month survey . Br J Urol. 74:1994;579-584.
66. Lepor H., Kaplan S.A., Klimberg I., et al. Doxazosin for benign prostatic hyperplasia long-term efficacy and safety in hypertensive and normotensive patients . J Urol. 157:1997;525-530.
67. Lukacs B., Grange J.C., McCarthy C., et al. Clinical uroselectivity a 3-year follow-up in general practice . Eur Urol. 33:1998;28-33.
68. Mobley D.F., Dias N., Levenstein M. Effects of doxazosin in patients with mild, intermediate, and severe benign prostatic hyperplasia. Clin Ther. 20:1998;101-109.
69. Kaplan S.A., Soldo K.A., Olsson C.A. Terazosin and doxazosin in normotensive men with symptomatic prostatism a pilot study to determine the effect of dosing regimen on efficacy and safety . Eur Urol. 28:1995;223-228.
70. Buzelin J.M., Fonteyne E., Kontturi M., et al. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol. 80:1997;597-605.
71. 1A-adrenoreceptor antagonists in benign prostatic hyperplasia studies on tamsulosin in a fixed dose and terazosin in increasing doses . Br J Urol. 80:1997;606-611.
72. Gormley G.J., Stoner E., Bruskewitz R.C., et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1992;1185-1191.
73. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 43:1994;284-294.
74. Andersen J.T., Ekman P., Wolf H., et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology. 46:1995;631-637.
75. Marberger M.J. Long-term effects of finasteride in patients with benign prostatic hyperplasia a double-blind, placebo-controlled, multicenter study . Urology. 51:1998;677-686.
76. Tenover J.L., Pagano G.A., Morton A.S., et al. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia a primary care study . Clin Ther. 19:1997;243-258.
77. Stoner E., Group F.S. The clinical effects of a 5 α-reductase inhibitor, finasteride, on benign prostatic hyperplasia. J Urol. 147:1992;1298-1302.
78. Kaplan S.A., Olsson C.A. Patient satisfaction with finasteride in the treatment of symptomatic benign prostatic hyperplasia. Clin Ther. 18:1996;73-83.
79. Andersen J.T., Nickel J.C., Marshall V.R., et al. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology. 49:1997;839-845.
80. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:1998;557-563.
81. Cormio L., Bloem F., Laduc R., et al. Pain sensation in transurethral microwave thermotherapy for benign prostatic hyperplasia the rationale for prophylactic sedation . Eur Urol. 25:1994;36-39.
82. de Wildt M.J., Debruyne F.M., de la Rosette J.J. High-energy transurethral microwave thermotherapy a thermoablative treatment for benign prostatic obstruction . Urology. 48:1996;416-423.
83. de la Rosette J.J.M.C.H., de Wildt M.J.A.M., Höfner K., et al. High energy thermotherapy in the treatment of benign prostatic hyperplasia results of the European Benign Prostatic Hyperplasia Study Group . J Urol. 156:1996;97-101.
84. Djavan B., Shariat S., Schäfer B., et al. Tolerability of high-energy transurethral microwave thermotherapy (TUMT) under topical urethral anesthesia results of a prospective, randomized, single-blinded clinical trial . J Urol. 160:1998;772-776.
85. Blute M.L., Tomera K.M., Hellerstein D.K., et al. Transurethral microwave thermotherapy for management of benign prostatic hyperplasia results of the United States Prostatron Cooperative Study . J Urol. 150:1993;1591-1596.
86. Kirby R.S., Williams G., Witherow R., et al. The Prostatron transurethral microwave device in the treatment of bladder outflow obstruction due to benign prostatic hyperplasia. Br J Urol. 72:1993;190-194.
87. Laduc R., Bloem F.A.G., Debruyne F.M.J. Transurethral microwave thermotherapy in symptomatic benign prostatic hyperplasia. Eur Urol. 23:1993;275-281.
88. Tubaro A., Paradiso Galatioto G., Trucchi A., et al. Transurethral microwave thermotherapy in the treatment of symptomatic benign prostatic hyperplasia. Eur Urol. 23:1993;285-291.
89. van Cauwelaert R.R., Castillo O.C., Aquirre C.A., et al. Transurethral microwave thermotherapy for the treatment of benign prostatic hyperplasia preliminary experience . Eur Urol. 23:1993;282-284.
90. Terai A., Arai Y., Onishi H., et al. Transurethral microwave thermotherapy for benign prostatic hyperplasia clinical results after a 1-year follow-up . Int J Urol. 2:1995;24-28.
91. Dahlstrand C., Grundtman S., Pettersson S. High-energy transurethral microwave thermotherapy for large severely obstructing prostates and the use of biodegradable stents to avoid catheterization after treatment. Br J Urol. 79:1997;907-909.
92. Devonec M., Dahlstrand C. Temporary urethral stenting after high-energy transurethral microwave thermotherapy of the prostate. World J Urol. 16:1998;120-123.
93. Djavan B, Fakhari M, Shariat S, et al: A novel intraurethral prostatic bridge-catheter for prevention of temporary prostatic obstruction following high-energy transurethral microwave thermotherapy in patients with benign prostatic hyperplasia. J Urol (in press).
94. Netto N.R., de Almeida Claro J., Cortado P.L. Ejaculatory dysfunction after transurethral microwave thermotherapy for treatment of benign prostatic hyperplasia. J Endourol. 8:1994;217-219.
95. Debruyne F.M., Witjes W.P., Fitzpatrick J., et al. The international terazosin trial a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia . Eur Urol. 30:1996;369-376.
96. Witjes W.P., Rosier F.W., de Wildt M.J., et al. Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia. J Urol. 155:1996;1317-1323.
97. McKiernan J.M., Lowe F.C. Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. South Med J. 90:1997;509-513.
98. Lukacs B., Blondin P., MacCarthy C., et al. Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur Urol. 29:1996;29-35.
99. Byrnes C.A., Morton A.S., Liss C.L., et al. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia a community-based study . Clin Ther. 17:1995;956-969.
100. Bdesha A.S., Schachter M., Sever P., et al. Radioligand-binding analysis of human prostatic alpha-1 adrenoreceptor density following transurethral microwave therapy. Br J Urol. 78:1996;886-892.